Oryzon Genomics S.A. (ORYZF)
Oryzon Genomics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cornellà de Llobregat, CT, ES. The stock last traded at $3.37, down 3.71% on the session, giving a market capitalisation of $276.2M. On trailing twelve-month figures it carries a trailing P/E of -93.14, a net margin of 0.0%. Its beta of 0.45 implies it has historically moved less than the broad market.
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous diseases. Established in 2000, Oryzon Genomics is headquartered in Cornellà de Llobregat, Spain.
Oryzon Genomics S.A. is most often compared with the following Healthcare names: